Pretreatment can alleviate programmed cell death in mesenchymal stem cells

Xin-Xing Wan; Xi-Min Hu; Qi Zhang; Kun Xiong

doi:10.4252/wjsc.v16.i8.773

Pretreatment can alleviate programmed cell death in mesenchymal stem cells

World J Stem Cells. 2024 Aug 26;16(8):773-779. doi: 10.4252/wjsc.v16.i8.773.

Authors

Xin-Xing Wan¹, Xi-Min Hu², Qi Zhang³, Kun Xiong⁴

Affiliations

¹ Department of Endocrinology, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan Province, China.
² Department of Dermatology, Xiangya Hospital, Central South University, Changsha 410008, Hunan Province, China.
³ Department of Anatomy and Neurobiology, Central South University, Changsha 410000, Hunan Province, China.
⁴ Department of Anatomy and Neurobiology, School of Basic Medical Science, Central South University, Changsha 410013, Hunan Province, China. xiongkun2001@163.com.

Abstract

In this editorial, we delved into the article titled "Cellular preconditioning and mesenchymal stem cell ferroptosis." This groundbreaking study underscores a pivotal discovery: Ferroptosis, a type of programmed cell death, drastically reduces the viability of donor mesenchymal stem cells (MSCs) after engraftment, thereby undermining the therapeutic value of cell-based therapies. Furthermore, the article proposes that by manipulating ferroptosis mechanisms through preconditioning, we can potentially enhance the survival rate and functionality of MSCs, ultimately amplifying their therapeutic potential. Given the crucial role ferroptosis plays in shaping the therapeutic outcomes of MSCs, we deem it imperative to further investigate the intricate interplay between programmed cell death and the therapeutic effectiveness of MSCs.

Keywords: Apoptosis; Autophagy; Ferroptosis; Mesenchymal stem cells; Programmed cell death.

Publication types

Editorial